'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC) Journal Article

  


Authors: Pao, W.; Miller, V. A.; Kris, M. G.
Article Title: 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
Abstract: Gefitinib (ZD1839, Iressa®), a selective drug inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK), was recently approved for the treatment of patients with advanced non-small cell lung cancer (NSCLC). This article reviews the identification of EGFR as a therapeutic target and the steps in the development of gefitinib as "targeted" monotherapy for patients with NSCLC. Whether EGFR is required for the maintenance of lung tumor survival is also discussed. Finally, strategies to identify predictors of response to gefitinib are explored. © 2003 Elsevier Ltd. All rights reserved.
Keywords: protein kinase b; protein expression; clinical trial; drug tolerability; review; diarrhea; protein domain; animals; gene overexpression; drug eruption; gene amplification; stress activated protein kinase; lung non small cell cancer; carcinoma, non-small-cell lung; lung neoplasms; epidermal growth factor receptor; receptor, epidermal growth factor; enzyme activity; protein tyrosine kinase; phosphatidylinositol 3 kinase; sarcoma; lung adenocarcinoma; glioblastoma; gefitinib; phase 1 clinical trial; sequence homology; ic 50; quinazolines; virus strain; non-small cell lung cancer; ligand binding; clinical trials; cancer cell destruction; signaling lymphocyte activation molecule associated protein; drug conformation; incubation time; tumor maintenance; zd1839; target cell destruction; humans; human; epidermal growth factor receptor tyrosine kinase inhibitor; gefitinib (iressa®); erythroblastosis
Journal Title: Seminars in Cancer Biology
Volume: 14
Issue: 1
ISSN: 1044-579X
Publisher: Academic Press Inc., Elsevier Science  
Date Published: 2004-02-01
Start Page: 33
End Page: 40
Language: English
DOI: 10.1016/j.semcancer.2003.11.005
PROVIDER: scopus
PUBMED: 14757534
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-0742321974&partnerID=40&md5=3fa59f3ef84f1edf6fa7c67d6583c88b
Notes: Semin. Cancer Biol. -- Cited By (since 1996):37 -- Export Date: 16 June 2014 -- CODEN: SECBE -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. William Pao
    141 Pao
  2. Vincent Miller
    270 Miller
  3. Mark Kris
    869 Kris
Related MSK Work